Esperion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces $75 Million Public Offering of Common Stock at $2.50 Per Share
Esperion Therapeutics Inc. (Nasdaq: ESPR), a commercial-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients with elevated LDL cholesterol, has announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at $2.50 per share. The company expects to raise approximately $75 million in gross proceeds, before deducting underwriting discounts, commissions, and other offering expenses. Esperion has also granted underwriters a 30-day option to purchase up to an additional 4,500,000 shares. Piper Sandler & Co. and Cantor Fitzgerald & Co. are serving as joint book-running managers for the offering, with Citizens JMP Securities, H.C. Wainwright & Co., and Needham & Company acting as co-managers. All shares in the offering will be sold by Esperion. The transaction is expected to close subject to customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541984-en) on October 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.